Search

BiomX Inc. announced positive results from Part 1 of the Phase 1b/2a trial evaluating their novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

Erytech (a red blood cell-based therapeutics company) and Pherecydes (a phage therapy company) will merge to form a new company, whose name is yet to be disclosed, and redirect Erytech's financial resources, people and network toward Pherec

The Japanese government is moving forward with a pull incentive for developing new antibiotics, called the Antimicrobial Securement Project. According to CARB-X's director, Kevin Outterson, this is a revenue guarantee pull incentive, akin t

Vésale Bioscience, a Belgian phage therapy company, has been awarded a €1.8m grant from the European Innovation Council to develop a phage therapy diagnostic platform to fight multidrug-resistant infections.

Technophage, a phage biotech company in Portugal, successfully completed its Phase I/IIa Clinical Trial of TP-102, a phage cocktail for infected diabetic foot ulcers.

Fixed Phage, a biotechnology company based in Glasgow, has secured £1.5 million in funding to further develop and commercialize its phage technology.

The FDA approved Rebyota, the first fecal microbiota product, for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older. Rebyota is administered rectally as a single dose and is pr

Innovate UK KTN has launched the Phage Innovation Network to drive innovation in the regulation and development of phage technologies for applications across multiple sectors, ensuring the UK maintains its strong stance on tackling antimicr

Eligo Bioscience just announced the issuance by the US Patent and Trademark Office of the first patent in a wide family covering genetic engineering of Cutibacterium acnes to support therapeutic interventions in multiple serious skin disord

Micreos, a Dutch/Swiss biotech company, has secured its next funding round of €25 million in growth capital for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.

Eligo Bioscience announced that the U.S. FDA has granted Orphan Drug Designation and Rare Pediatric Disease designation for EB003, their oral drug candidate for the treatment of Shiga-toxin producing bacterial infection.

Phagos, a French phage manufacturing company, announced the closing of a €2.4 million Seed investment round co-led by Demeter (Paris) and Hoxton Ventures (London).

Adaptive Phage Therapeutics (APT) has announced that the Defense Health Agency (DHA) has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage therapy in treatment of diabetic foot osteomyelitis (D

News: Locus Biosciences announces first patient treated in the ELIMINATE phase 2/3 trial for urinary tract infections.

Adaptive Phage Therapeutics announces "The AMR RAPID™ Challenge": APT will pay $1000 to to any individual or institution in the clinical research community who can find a bacteria resistant to their investigational Phage Bank.

Felix Biotechnology has been awarded a Small Business Innovation Research (SBIR) Phase I grant for $314,411 from the National Institute of Health (NIH) to develop a microfluidics platform for rapid, high-throughput screening of therapeutic

BiomX has reported findings from a phase 1a clinical trial of its K. pneumoniae-specific phage candidate BX002. They randomized 18 healthy adults to take either a phage cocktail or placebo orally. They looked at viable phage in stool, and c

Paper: Phage-antibiotic combination therapy for multidrug-resistant P. aeruginosa: In vitro synergy testing.

News: LyseNTech, a Korean phage company led by Heejoon Myung, was named a leading research institute by the Korean Ministry of Trade, Industry and Energy. LyseNTech aims to develop 'LNT103', a phage-derived endolysin, as an inhaled treatmen

Phase Genomics raised $5.5M from the Bill and Melinda Gates Foundation & NIH to catalog the viruses that infect bacteria. The resulting database could be used to develop new therapeutics & build a surveillance system to detect & respond to